Abstract
The standard surgical treatment option for peritoneal carcinomatosis (PC) is cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). This is an aggressive and complex treatment that often involves multi-visceral resection including extensive peritonectomies, splenectomy, bowel resections, and removal of other major organs that are involved with tumor. Upon completion of surgical extirpation of tumor, heated chemotherapy is instilled into the peritoneal cavity, and the abdomen is agitated for 60–120 min. The extensive nature of these procedures is associated with longer and more complicated anesthetic administration.
There are many challenges for the anesthetic team related to blood loss, temperature shifts, extensive fluid loss, and toxicity related to chemotherapy. A basic knowledge of chemotherapy drugs that are used during the HIPEC phase is also needed. A thorough understanding of this multimodal treatment is necessary to keep the patients safe during all phases of perioperative care.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Albalawi Z, et al. The impact of the implementation of the enhanced recovery after surgery program in an entire health system: a natural experiment in Alberta, Canada. World J Surg. 2018;42:2691–700.
Arakelian E, et al. Pulmonary influences on early post-operative recovery in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy treatment: a retrospective study. World J Surg Oncol. 2012;10(1):258.
Balakrishnan KP, Survesan S. Anaesthetic management and perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a retrospective analysis.. India/ija 39 18n. J Anaesth. 2018;62(3):188–96. https://doi.org/10.4103/ija.IJA_39_18.
Bhagwandin SB, et al. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge. J Surg Oncol. 2018;111(3):324. https://doi.org/10.1002/jso.23834al.
Cata JP, et al. Identification of risk factors associated with postoperative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a retrospective study. Int J Hyperth. 2017; https://doi.org/10.1080/02656736.2017.1368096.
Colantonia L, et al. A randomized trial of goal directed vs. standard fluid therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Gastrointest Surg. 2015;19(4):722–9. https://doi.org/10.1007/s11605-015-2743-1. Epub 2015 Jan 17
Eng OS, et al. Association of fluid administration with morbidity in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. JAMA Surg. 2017;152(12):1156–60. https://doi.org/10.1001/jamasurg.2017.2865.
Helander EM et al. A comparison of multimodal analgesic approaches in institutional enhanced recovery after surgery protocols for colorectal surgery: pharmacological agents. 2017. Memtsoudis, et al. Association of multimodal pain management strategies with perioperative outcomes and resource utilization: a populations based study. Anesthesiology. 2018. 2018. https://doi.org/10.1097/aln.0000000000002132. PubMed 22. PMID:29498951; eng.
Fischer SB, et al. Elevated brain natriuretic peptide (BNP) is an early marker for patients at risk for complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS+ HIPEC). J Surg Oncol. 2017;117(4):685. https://doi.org/10.1002/jso.24904.
Hendrix RJ, et al. Restrictive intraoperative fluid therapy is associated with decreased morbidity and length of stay following hyperthermic intraperitoneal chemoperfusion. Ann Surg Oncol. 2018; https://doi.org/10.1245/s10434-018-07092-y.
Kadji ME, et al. Anaesthesia in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: retrospective analysis of a single centre three-year experience. World J Surg Oncol. 2014;12:136. https://doi.org/10.1186/1477-7819-12-136.
Kapoor S, et al. Critical care management and intensive care unit outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. World J Crit Care Med. 2017;6(2):116–23. https://doi.org/10.5492/wjccm.v6.i2.116.
Laqm JY, et al. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and highgrade appendiceal peritoneal carcinomatosis. Am J Surg. 2015;210(3):424–30.
Malfroy S, et al. Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: risk factors for ICU admission and morbidity prognostic score. Surg Oncol. 2016;25(1):6–15.
Martin TD, et al. Newly implemented enhanced recovery pathway positively impacts hospital length of stay. Surg Endosc. 2016;30(9):4019–28.
Martin LW, et al. Implementing a thoracic enhanced recovery program: lessons learned in the first year. Ann Thorac Surg. 2018;105(6):1597–604.
Owusu-Agyemang P, et al. Anesthetic management and renal function in pediatric patients undergoing cytoreductive surgery with continuous hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin. Ann Surg Oncol. 2012;19(8):2652–6. https://doi.org/10.1245/s10434-012-2319-1. Epub 2012 Mar27
Owusu-Agyemang P, et al. Evaluating the impact of total intravenous anesthesia on the clinical outcomes and perioperative NLR and PLR profiles of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(8):2419–29. https://doi.org/10.1245/s10434-016-5176-5. Epub 2016M
Rodriquez M. Locoregional methods for management and palliation in patients who present with stage 1V colorectal cancer. Uptodate. 2018.
Schneider MA, et al. Major postoperative complications are a risk factor for impaired survival after CRS/HIPEC. Ann Surg Oncol. 2017;24(8):2224–32.
Smith HJ, et al. Impact of enhanced recovery after surgery (ERAS) protocol on postoperative pain control in chronic narcotic users. Gynecol Oncol. 2018;149:19.
Thiele RH, et al. Standardization of care: impact of enhanced recovery protocol on length of stay, complications, and direct costs after colorectal surgery. J Am Coll Surg. 2015;220(4):430–43.
Thiele RH, for the Perioperative Quality Initiative (POQI) I Workgroup, et al. American Society for Enhanced Recovery (ASER) and Perioperative Quality Initiative (POQI) joint consensus statement on perioperative fluid management Jo within an enhanced recovery pathway for colorectal surgery. Perioper Med. 2016;5(1):1–15.
Valle SJ, et al. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: incidence, management and outcomes. Surg Oncol. 2016;25(3):315–20. https://doi.org/10.1016/j.suronc.2016.0.025.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this entry
Cite this entry
Hurst, D., Owusu-Agyemang, P. (2020). Perioperative Management of the Oncologic Patient Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC). In: Nates, J., Price, K. (eds) Oncologic Critical Care. Springer, Cham. https://doi.org/10.1007/978-3-319-74588-6_174
Download citation
DOI: https://doi.org/10.1007/978-3-319-74588-6_174
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-74587-9
Online ISBN: 978-3-319-74588-6
eBook Packages: MedicineReference Module Medicine